Genfit SA

GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025

28 Apr 2025 16:10:00 By Nasdaq GlobeNewswire

GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update

24 Apr 2025 16:10:00 By Nasdaq GlobeNewswire

GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders

20 Mar 2025 17:10:00 By Nasdaq GlobeNewswire

Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs

10 Mar 2025 17:10:00 By Nasdaq GlobeNewswire

GENFIT Announces Revenues and Cash Position as of December 31, 2024

27 Feb 2025 16:10:00 By Nasdaq GlobeNewswire

GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders’ general meeting

21 Feb 2025 02:30:00 By Nasdaq GlobeNewswire

GENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the 2025 OCEANEs Holders

14 Feb 2025 16:10:00 By Nasdaq GlobeNewswire

GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders

10 Feb 2025 01:30:00 By Nasdaq GlobeNewswire

GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025

06 Feb 2025 16:10:00 By Nasdaq GlobeNewswire

GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan

30 Jan 2025 02:40:00 By Nasdaq GlobeNewswire

GENFIT Announces 2025 Financial Calendar

29 Jan 2025 16:10:00 By Nasdaq GlobeNewswire

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

13 Jan 2025 16:10:00 By Nasdaq GlobeNewswire

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024

13 Nov 2024 16:10:00 By Nasdaq GlobeNewswire

GENFIT Reports Third Quarter 2024 Financial Information

07 Nov 2024 16:10:00 By Nasdaq GlobeNewswire

GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval

23 Sep 2024 01:30:00 By Nasdaq GlobeNewswire

GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update

19 Sep 2024 16:10:00 By Nasdaq GlobeNewswire

GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis

26 Jul 2024 07:45:00 By Nasdaq GlobeNewswire

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

09 Jul 2024 16:10:00 By Nasdaq GlobeNewswire

GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH

17 Jun 2024 16:10:00 By Nasdaq GlobeNewswire

GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis

10 Jun 2024 17:22:00 By Nasdaq GlobeNewswire